[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) [clinicaltrials:NCT00000135]Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) [clinicaltrials:NCT00000136]Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) [clinicaltrials:NCT00000143]clinicaltrials:NCT00000170Neurobiology of Opioid Dependence: 1 - 1 [clinicaltrials:NCT00000192]Neurobiology of Opioid Dependence: 2 - 2 [clinicaltrials:NCT00000193]Neurobiology of Opioid Dependence: 3 - 3 [clinicaltrials:NCT00000194]Neurobiology of Opioid Dependence: 4 - 4 [clinicaltrials:NCT00000195]Neurobiology of Opioid Dependence: 5 - 5 [clinicaltrials:NCT00000196]Buprenorphine Maintenance for Opioid Addicts - 1 [clinicaltrials:NCT00000202]Buprenorphine Maintenance for Opioid Addicts - 2 [clinicaltrials:NCT00000203]Buprenorphine Maintenance for Opioid Addicts - 3 [clinicaltrials:NCT00000204]Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 [clinicaltrials:NCT00000210]Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 [clinicaltrials:NCT00000211]IV Cocaine Abuse: A Laboratory Model - 1 [clinicaltrials:NCT00000212]IV Cocaine Abuse: A Laboratory Model - 2 [clinicaltrials:NCT00000213]IV Cocaine Abuse: A Laboratory Model - 3 [clinicaltrials:NCT00000214]Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 [clinicaltrials:NCT00000217]Effects of Dynorphin 1-13 on Heroin Addiction - 1 [clinicaltrials:NCT00000244]Effects of Subanesthetic Concentrations of Nitrous Oxide - 1 [clinicaltrials:NCT00000249]Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2 [clinicaltrials:NCT00000250]clinicaltrials:NCT00000251Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4 [clinicaltrials:NCT00000252]Effects of Nitrous Oxide: A Dose-Response Analysis - 5 [clinicaltrials:NCT00000253]Isoflurane at Subanesthetic Concentrations - 6 [clinicaltrials:NCT00000254]Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7 [clinicaltrials:NCT00000255]Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8 [clinicaltrials:NCT00000256]Effects of Alcohol History on Effects of Nitrous Oxide - 9 [clinicaltrials:NCT00000257]Role of Instructions in Nitrous Oxide Effects and Choice - 10 [clinicaltrials:NCT00000258]Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11 [clinicaltrials:NCT00000259]Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12 [clinicaltrials:NCT00000260]Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 [clinicaltrials:NCT00000261]Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14 [clinicaltrials:NCT00000262]Effects of Combined Alcohol and Nitrous Oxide Intake - 15 [clinicaltrials:NCT00000263]Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16 [clinicaltrials:NCT00000264]Subjective Effects of Nitrous Oxide in Dental Patients - 17 [clinicaltrials:NCT00000265]A Laboratory Model for Heroin Abuse Medications - 8 [clinicaltrials:NCT00000273]Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 [clinicaltrials:NCT00000276]Mazindol for Cocaine Abuse - 2 [clinicaltrials:NCT00000277]
responsible party [clinicaltrials_vocabulary:responsible-party]
[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]
Bio2RDF identifier
dbd41868ee618d3e64daa1adf8c3a8a0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0
type
label
[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]
@en